Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) and Foghorn Therapeutics (NASDAQ:FHTX – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.
Analyst Ratings
This is a summary of current recommendations for Amylyx Pharmaceuticals and Foghorn Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Amylyx Pharmaceuticals | 1 | 0 | 6 | 2 | 3.00 |
| Foghorn Therapeutics | 1 | 6 | 4 | 0 | 2.27 |
Amylyx Pharmaceuticals currently has a consensus target price of $44.14, suggesting a potential upside of 49.64%. Foghorn Therapeutics has a consensus target price of $6.14, suggesting a potential upside of 228.50%. Given Foghorn Therapeutics’ higher possible upside, analysts clearly believe Foghorn Therapeutics is more favorable than Amylyx Pharmaceuticals.
Risk and Volatility
Amylyx Pharmaceuticals has a beta of -0.09, indicating that its share price is 109% less volatile than the S&P 500. Comparatively, Foghorn Therapeutics has a beta of 3.22, indicating that its share price is 222% more volatile than the S&P 500.
Valuation & Earnings
This table compares Amylyx Pharmaceuticals and Foghorn Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Amylyx Pharmaceuticals | N/A | N/A | -$144.74 million | ($1.44) | -20.49 |
| Foghorn Therapeutics | $36.74 million | 3.02 | -$74.28 million | ($0.98) | -1.91 |
Foghorn Therapeutics has higher revenue and earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Amylyx Pharmaceuticals and Foghorn Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Amylyx Pharmaceuticals | N/A | -41.54% | -38.91% |
| Foghorn Therapeutics | -175.78% | N/A | -31.17% |
Insider & Institutional Ownership
95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 61.5% of Foghorn Therapeutics shares are owned by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are owned by company insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Foghorn Therapeutics beats Amylyx Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.
About Foghorn Therapeutics
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Amylyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amylyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
